Aurobindo Pharmaceuticals' Q3FY19 numbers were higher than Idirect estimates due to higher-than-expected sales in all geographies except the US. Revenues grew 21.5% YoY to | 5269.7 crore (I-direct estimate: | 5022.3 crore) mainly due to 27.4% YoY growth in the US EBITDA margins contracted 344 bps YoY to 20.7% (I-direct estimate: 21.0%) mainly due to lower gross margins. EBITDA grew 6.2% to | 1089 crore against I-direct estimate of | 1055.5 crore Adjusted net profit grew 25.4% YoY to | 737.3 crore (I-direct estimate: | 669.1 crore). The delta vis--vis EBITDA was due to...